drugset / Trial / NCT01361555

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01361555

Phase 2 Terminated 789 enrolled Bristol-Myers Squibb
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study it to evaluate the long-term safety and tolerability of BMS-820836 in patients with depression.

Timeline

Start
2011-08
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Liafensine Small molecule 0.5 mg Oral
Subject Liafensine Small molecule 1 mg Oral
Subject Liafensine Small molecule 2 mg Oral